LENZ Therapeutics (LENZ) Cash & Equivalents (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash & Equivalents data on file, last reported at $24.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $24.8 million, up 7.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.8 million (up 7.51% YoY), and the FY2025 annual result was $25.2 million, up 24.91% from the prior year.
• Cash & Equivalents retreated to $24.8 million in Q1 2026 per LENZ's latest filing, from $25.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $200.4 million in Q1 2024 and troughed at $8.0 million in Q1 2023.
• A 5-year average of $70.6 million and a median of $41.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 95.7% in 2023, then soared 2416.42% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $47.7 million in 2022, then decreased by 26.38% to $35.1 million in 2023, then plunged by 42.64% to $20.2 million in 2024, then grew by 24.91% to $25.2 million in 2025, then retreated by 1.62% to $24.8 million in 2026.
• Business Quant data shows LENZ's Cash & Equivalents at $24.8 million in Q1 2026, $25.2 million in Q4 2025, and $25.4 million in Q3 2025.